(Q69801500)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

title

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

main subject

Pseudomonas aeruginosa

1 reference

6

R R Muder

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

author name string

M Hilf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

V L Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

J Sharp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

J J Zuravleff

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

J A Korvick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

publication date

1 November 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

5 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

volume

87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

page(s)

540-546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

Combinations of antibiotics against Pseudomonas aeruginosa

5 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Nosocomial infections due to Pseudomonas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Pseudomonas aeruginosa bacteremia in patients with neoplastic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Secular trends in nosocomial infections: 1970-1979

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Pseudomonas bacteremia. Review of 108 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Pseudomonas bacteremia in patients with malignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Interaction of clindamycin and gentamicin in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Correlations between methods for measurement of synergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Empirical antimicrobial therapy in the neutropenic host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Antimicrobial Synergism--An Elusive Concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Comparison of Techniques for Measurement of in Vitro Antibiotic Synergism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Synergy of Carbenicillin and Gentamicin in Experimental Infection with Pseudomonas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Therapy of neutropenic rats infected with Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Effectiveness of gentamicin and carbenicillin in a rat model against infections with Pseudomonas aeruginosa resistant to gentamicin or gentamicin and carbenicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Comparison of Antibiotic Regimens for Treatment of Experimental Pneumonia Due to Pseudomonas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Comparison of gentamicin, carbenicillin and gentamicin, and carbenicillin in Pseudomonas sepsis in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

A Randomized Comparative Trial of Three Aminoglycosides—Comparison of Continuous Infusions of Gentamicin, Aaikacin and Sisomicin Combined with Carbenicillin in the Treatment of Infections in Neutropenic Patients with Malignancies

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Improved prognosis for granulocytopenic patients with gram-negative bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Pseudomonas Bacteremia: Pharmacologic and Other Bases for Failure of Treatment with Gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Carbenicillin Therapy for Pseudomonas Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Why Monitor Serum Levels of Gentamicin?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

The assessment of antimicrobial combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

Significance of antimicrobial synergism for the outcome of gram negative sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2889%2980611-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(89)80611-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2816969%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

1 reference